Windy City Media Group Frontpage News
Celebrating 30 Years of Gay Lesbian Bisexual and Trans News
home search facebook twitter join
Gay News Sponsor Windy City Times 2019-06-19
DOWNLOAD ISSUE
About WCMG Publications News Index  Entertainment Features Bars & Clubs Calendar Videos Advertisers OUT! Guide    Marriage

Sponsor
Sponsor
Sponsor

  WINDY CITY TIMES

Five reasons the Gilead deal is a steaming pile of Truvada
by Mark S. King
2019-05-22

facebook twitter google +1 reddit email


Gilead Sciences, the pharmaceutical that makes Truvada, the only FDA-approved drug for PrEP, is having a great week in the public relations department. First, Gilead announced they were surrendering their patent for Truvada a year early, and now Federal officials have announced that Gilead will donate enough Truvada for 200,000 people in the United States.

Don't fall for this. Gilead is engaged in a brilliantly self-serving marketing ploy and dressing it up like charity. Their deeply entrenched ownership of our governmental and community HIV response is as clear as ever. This ownership isn't absolute; there are activists and national community leaders who see this ploy for what it is. #PrEP4All has met the news with great skepticism, and national non-profit leaders, who depend upon Gilead funding, have damned the announcement with faint praise.

Here are five reasons why Gilead is simply building profits and ignoring pleas to do some real good.

1. Gilead is offering no-cost Truvada for 200,000 when it could make it affordable for everyone.

It costs Gilead pennies to make Truvada. It charges $20,000 a year for it. If Gilead really wanted to end this epidemic—and make no mistake, they have the ability to fundamentally alter the trajectory of HIV in the United States—then it would lower the price of Truvada across the board, for everyone. And by lower, I mean by a lot.

And the math is way off. We don't need 200,000 more people on PrEP. We need a million more people on PrEP.

Did I mention that Gilead will claim many, many millions of dollars in lost revenue on their corporate taxes as a result of their generosity?

2. Gilead is only providing Truvada for non-insured persons. People with insurance need it just as much.

There are people with health insurance who still face barriers to PrEP. They have high deductibles and co-pays, for instance, or they take one look at the bureaucracy of prior authorizations and co-pay assistance cards and just give up.

3. Gilead's big donation creates new customers for its new PrEP drug, Descovy.

This might be Gilead at their most vile. By offering free Truvada to 200,000 people, they are creating a customer base for the arrival of their new drug, Descovy, which awaits FDA approval for use as PrEP.

Descovy does not cause the side effects that Truvada patients have had. Gilead knew about the Truvada side effects years ago, but they waited all this time to introduce Descovy because they wanted to run out the clock on Truvada's patent, yes, even while knowing Truvada was causing debilitating side effects in thousands of people along the way. This is just another chapter in the rich, sick history of Gilead's corporate profiteering.

4. Gilead is unloading an obsolete PrEP drug and charging full price for its new one.

Once Descovy is FDA-approved next year for PrEP, Gilead will have an additional 200,000 new Truvada customers that they can try and talk into taking their new, improved version. For which they will be charging the full price of $20,000 per year.

5. The Truvada-as-PrEP patent belongs to U.S. taxpayers. Where are the royalties we deserve?

This brings us to the topic Gilead really, really wants everyone to stop talking about. The patents for Truvada-as PrEP belong to the United States taxpayers because the research was done by the CDC, not Gilead. Considering Gilead makes $3 billion a year on the sale of Truvada, those royalties could fund our national HIV prevention response. The CDC will not discuss this.

Oh, and the CDC owns patents to Descovy-as-PrEP, too. Don't expect all the #PrEP4All activism to fade when Truvada goes generic. It won't.

Gilead is hoping that its one-day headline about its Truvada donation will appease critics of their profiteering. It does not. And from what I am hearing, there are many more headlines to come in the days ahead.

Mark S. King is a GLAAD Award nominee for his blog, My Fabulous Disease, and author of A Place Like This, his memoir of Los Angeles during the dawn of AIDS.


facebook twitter google +1 reddit email





Windy City Media Group does not approve or necessarily agree with the views posted below.
Please do not post letters to the editor here. Please also be civil in your dialogue.
If you need to be mean, just know that the longer you stay on this page, the more you help us.


  ARTICLES YOU MIGHT LIKE

Gay News

People with disabilities wanted to talk about justice system 2019-06-23 - Access Living, a local disability rights and advocacy organization, is seeking people with disabilities who have had contact with the Cook County criminal ...


Gay News

Walgreens, Greater Than AIDS offering free tests June 27 2019-06-23 - Walgreens and Greater Than AIDS are partnering community organizations across Chicago to provide free, confidential HIV testing and counseling in 22 Chicago Walgreens ...


Gay News

Title X gag rule begins, limiting health care access for many, Planned Parenthood responds 2019-06-20 - WASHINGTON —— The Trump-Pence administration's Title X gag rule takes effect today in every state but Maryland, after a ruling by a panel ...


Gay News

AMA adopts new pro-LGBTQ policies at annual meeting 2019-06-19 - The American Medical Association ( AMA ), voted to adopt new policies on emerging health care topics during the first day of voting ...


Gay News

Reproductive Health Act is law, making Illinois a 'beacon' 2019-06-19 - CHICAGO—Democratic Gov. J.B. Pritzker made Illinois the most liberal state in the United States for access to reproductive health care with the strokes ...


Gay News

We remember, we celebrate, we believe 2019-06-18 - There is a lot of remembering, celebrating and believing going on right now. The "uprising" at the Stonewall Inn 50 years ago represents ...


Gay News

LETTER Respecting elders 2019-06-18 - Dear Editor: No one likes to talk about it, but it happens every day. However, this crisis remains vastly underidentified and underreported. ...


Gay News

Family Equality Council holds LGBTQ reproductive options panel discussion 2019-06-18 - Family Equality Council held an "LGBTQ+ Paths to Pregnancy: Using Donor Sperm to Build Your Family" panel discussion June 12 at Women & ...


Gay News

WORLD Conversion therapy, Bermuda march, trans officer, Belgium ban 2019-06-18 - Germany plans to ban all conversion therapies under a new law to be introduced this year by German Health Minister Jens Spahn, PinkNews ...


Gay News

Aging with HIV focus of Reunion Project event 2019-06-17 - The Reunion Project 2.0—Chicago hosted a two day event focused on people aging with HIV June 14-15 at Loyola University's Water Tower Campus. ...


 



Copyright © 2019 Windy City Media Group. All rights reserved.
Reprint by permission only. PDFs for back issues are downloadable from
our online archives. Single copies of back issues in print form are
available for $4 per issue, older than one month for $6 if available,
by check to the mailing address listed below.

Return postage must accompany all manuscripts, drawings, and
photographs submitted if they are to be returned, and no
responsibility may be assumed for unsolicited materials.
All rights to letters, art and photos sent to Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago
Gay and Lesbian News and Feature Publication) will be treated
as unconditionally assigned for publication purposes and as such,
subject to editing and comment. The opinions expressed by the
columnists, cartoonists, letter writers, and commentators are
their own and do not necessarily reflect the position of Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago Gay,
Lesbian, Bisexual and Transegender News and Feature Publication).

The appearance of a name, image or photo of a person or group in
Nightspots (Chicago GLBT Nightlife News) and Windy City Times
(a Chicago Gay, Lesbian, Bisexual and Transgender News and Feature
Publication) does not indicate the sexual orientation of such
individuals or groups. While we encourage readers to support the
advertisers who make this newspaper possible, Nightspots (Chicago
GLBT Nightlife News) and Windy City Times (a Chicago Gay, Lesbian
News and Feature Publication) cannot accept responsibility for
any advertising claims or promotions.

 

 

 

TRENDINGBREAKINGPHOTOS

Sponsor
Sponsor
Sponsor
Sponsor
Sponsor


 



About WCMG Publications News Index  Entertainment Features Bars & Clubs Calendar Videos Advertisers OUT! Guide    Marriage


About WCMG      Contact Us      Online Front  Page      Windy City  Times      Nightspots      OUT! Guide     
Identity      BLACKlines      En La Vida      Archives      Subscriptions      Distribution      Windy City Queercast     
Queercast Archives      Advertising  Rates      Deadlines      Advanced Search     
Press  Releases      Event Photos      Join WCMG  Email List      Email Blast     
Upcoming Events      Todays Events      Ongoing Events      Post an Event      Bar Guide      Community Groups      In Memoriam      Outguide Categories      Outguide Advertisers      Search Outguide      Travel      Dining Out      Blogs      Spotlight  Video     
Classifieds      Real Estate      Place a  Classified     

Windy City Media Group publishes Windy City Times,
The Bi-Weekly Voice of the Gay, Lesbian, Bisexual and Trans Community.
5315 N. Clark St. #192, Chicago, IL 60640-2113 • PH (773) 871-7610 • FAX (773) 871-7609.